Abdominal Imaging Division, Department of Radiology, University of Pittsburgh, 200 Lothrop Street, Pittsburgh, PA, 15213, USA; Section of Radiology - BiND., University Hospital "Paolo Giaccone", Via del Vespro 129, 90127, Palermo, Italy.
Section of Radiology - BiND., University Hospital "Paolo Giaccone", Via del Vespro 129, 90127, Palermo, Italy.
Eur J Radiol. 2019 Oct;119:108633. doi: 10.1016/j.ejrad.2019.08.002. Epub 2019 Aug 6.
To conduct an intraindividual comparison of the enhancement pattern of hepatocellular adenoma (HCA) on dynamic MRI study obtained following the injection of Gadoxetic acid (Gd-EOB-DTPA) and other gadolinium-based contrast agents (GBCAs).
This is a retrospective, Institutional Review Board-approved study conducted in a single institution. A search of medical records between 2008 and 2017 revealed 17 patients (all females) with at least one pathologically-proven HCA who underwent liver MRI with Gd-EOB-DTPA and another GBCA within 1 year. Enhancement of each lesion on hepatic arterial (HAP), portal venous (PVP), 2 min and 4-5 minutes phases was subjectively evaluated by two abdominal radiologists. Lesions were categorized as hyper-, iso- or hypointense compared to the surrounding liver parenchyma. The presence of a peripheral pseudocapsule was also recorded. The differences in lesion enhancement were assessed using the McNemar Test. A p-value <0.05 was considered statistically significant.
The final population included 35 HCAs (83% inflammatory subtype). There was no significant difference in lesion size (P = 0.708) and enhancement on HAP (P = 0.625) or PVP (P = 0.125). HCAs showed more frequently hypointensity on 2 min (13/35 vs. 1/35, P < 0.001) and 4-5 minutes (P < 0.001) images obtained after injection of Gd-EOB-DTPA compared to those obtained after other GBCAs. A pseudocapsule was more frequently noted after administration of Gd-EOB-DTPA (13/35 vs 1/35, P = 0.002).
Enhancement pattern of HCA differs significantly after the injection of Gd-EOB-DTPA compared to other GBCAs. Lesion hypointensity on 2 min and 4-5 minutes images is more frequent when using Gd-EOB-DTPA.
对注射钆塞酸(Gd-EOB-DTPA)和其他基于钆的对比剂(GBCA)后行肝脏 MRI 检查的肝细胞腺瘤(HCA)增强模式进行个体内比较。
这是一项在单中心进行的回顾性、经机构审查委员会批准的研究。2008 年至 2017 年间,通过病历检索发现 17 名(均为女性)至少有一个经病理证实的 HCA 患者,他们在 1 年内接受了 Gd-EOB-DTPA 和另一种 GBCA 的肝脏 MRI 检查。两位腹部放射科医生对每个病变在肝动脉(HAP)、门静脉(PVP)、2 分钟和 4-5 分钟期的强化情况进行了主观评估。病变与周围肝实质相比被分为高、等或低信号。还记录了假性包膜的存在。使用 McNemar 检验评估病变增强的差异。p 值<0.05 被认为具有统计学意义。
最终纳入 35 个 HCA(83%为炎症亚型)。病变大小(P=0.708)、HAP 增强(P=0.625)或 PVP 增强(P=0.125)差异无统计学意义。与其他 GBCA 相比,Gd-EOB-DTPA 注射后 2 分钟(13/35 比 1/35,P<0.001)和 4-5 分钟(P<0.001)图像上 HCA 更常表现为低信号。注射 Gd-EOB-DTPA 后更常观察到假性包膜(13/35 比 1/35,P=0.002)。
与其他 GBCA 相比,注射 Gd-EOB-DTPA 后 HCA 的增强模式有显著差异。使用 Gd-EOB-DTPA 时,2 分钟和 4-5 分钟图像上的病变低信号更为常见。